https: www.mdc berlin.de de veroeffentlichungstypen clinical journal club Frontiers Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals? Efficacy and safety of co administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination What is the pipeline for future medications for obesity? International Journal of Obesity The pharma race to develop increasingly more potent incretin based therapeuticswhat is for the clinicians to know